McKesson shares have put up a long run, and the stock now trades at a level where many holders are starting to ask whether the current price still lines up with the cash the business can generate over time. With that question front and center, the focus shifts from recent returns to what those cash flows suggest about an intrinsic value for the company today.
- Over the past 5 years the stock has returned 365.5%, which makes it important to check how much of that move is supported by the cash the business can realistically produce.
- The group relies on high volume distribution, tight working capital management and thin margins, so small changes in execution or pricing power can have an outsized impact on the cash available to shareholders.
- If you'd rather focus on earnings, this one's for you. See what McKesson's 23.2x P/E says about the price.
The issue now is whether McKesson's current share price is adequately backed by the cash flows implied by its intrinsic value estimate from the Discounted Cash Flow (DCF) approach.
If you are comparing McKesson with other valuation-focused opportunities, it can be useful to evaluate it alongside companies screened for 27 high quality undervalued stocks.
Does McKesson Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash McKesson can return to shareholders over time and discounts it back to today. On this model, the latest twelve month free cash flow sits at about $6.0b, which already reflects a sizeable cash engine behind the current share price of $915.45.
Analysts feeding into the DCF assume that free cash flow grows from that base, with multi year projections pointing to higher annual cash generation by the early 2030s. That path looks more like a mature business steadily expanding cash output than a turnaround story. On those cash flow assumptions and the discounting used, the DCF projections put McKesson's estimated intrinsic value substantially above the current share price, which is why the tool flags a gap between what the market is paying and what those projected dollars suggest the stock could be worth over time. Find out what McKesson could be worth using our Discounted Cash Flow (DCF) estimate.
The McKesson Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the DCF leaves off and explain which assumptions about McKesson's future growth, margins and earnings would need to occur for the stock to be worth significantly more or less than today, using the Community page as the home for those scenarios. Instead of a single output from one model, Narratives describe the path that number relies on so you can monitor how closely reality tracks that story over time.
One of the top community narratives on McKesson: 7% undervalued
"McKesson now leans more heavily on the oncology ecosystem, including US Oncology Network, PRISM and Precision Medicine Group, as a central driver..."
Discover why this Narrative puts McKesson at 7% undervalued.
One more crucial piece for McKesson that the numbers alone cannot answer
McKesson's cash flow story is only part of the picture, because the people steering the business and the way they are rewarded can heavily shape how those dollars are earned and shared. See who runs McKesson and how they are paid.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com